The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 18, 2019
Filed:
Jan. 20, 2016
Applicant:
Millennium Pharmaceuticals, Inc., Cambridge, MA (US);
Inventors:
Brian Scott Freeze, Boston, MA (US);
Kenneth M. Gigstad, Westford, MA (US);
David A. Janowick, Quincy, MA (US);
Hong Myung Lee, Cambridge, MA (US);
Zhan Shi, Concord, MA (US);
Francois Soucy, Stoneham, MA (US);
Stepan Vyskocil, Arlington, MA (US);
Assignee:
Millennium Pharmaceuticals, Inc., Cambridge, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/14 (2006.01); A61K 31/47 (2006.01); C07D 403/12 (2006.01); C07D 405/14 (2006.01); C07D 401/12 (2006.01); C07D 403/14 (2006.01); C07D 409/14 (2006.01); C07D 471/04 (2006.01); C07D 495/04 (2006.01); A61K 31/4709 (2006.01); A61K 31/501 (2006.01); A61K 31/517 (2006.01); A61K 31/541 (2006.01); C07D 215/233 (2006.01); C07D 401/04 (2006.01); C07D 417/12 (2006.01);
U.S. Cl.
CPC ...
C07D 401/14 (2013.01); A61K 31/47 (2013.01); A61K 31/4709 (2013.01); A61K 31/501 (2013.01); A61K 31/517 (2013.01); A61K 31/541 (2013.01); C07D 215/233 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01); C07D 495/04 (2013.01);
Abstract
This invention provides compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein T, J, R, R, R, o, R, W and Rand subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, and/or T-cell mediated autoimmune disease.